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Abstract
Non-alcoholic fatty liver disease is considered as an independent predictor of cardiovascular diseases which plays an
important role in the development of ischemic heart disease. The drug most frequently used for treating this comorbidity is
atorvastatin which favours better survival outcomes and is essential in the primary and secondary prevention of cardiovascular
diseases. Ursodeoxycholic acid is prescribed as an alternative therapy for ischemic heart disease with co-existent non-
alcoholic fatty liver disease and obesity to eliminate statin side effects. The use of ursodeoxycholic acid as a hepatoprotector
in comprehensive basic treatment contributes to the improvement of the cardiovascular system in patients with ischemic
heart disease as well as the increase in treatment efficacy; it improves the functional status of the liver affecting the major
pathogenic mechanisms of the disease.
The objective of the research was to study the effect of combined hypolipidemic therapy with atorvastatin and ursodeoxycholic
acid on the indices of blood lipids, liver transaminase levels, functional status of the liver and the course of non-alcoholic fatty
liver disease in patients with ischemic heart disease and obesity.
Materials and methods. 20 patients with ischemic heart disease, co-existent non-alcoholic fatty liver disease and obesity
were examined. They received ursodeoxycholic acid in addition to atorvastatin for four weeks. All the patients underwent
clinical tests, visceral ultrasonography, blood lipid test, liver transaminase test and 13C-methacetin breath test.
Results. The study revealed a significant decrease in the level of the pro-atherogenic fractions of blood lipids (p<0.01) as
well as an improved functional status of the liver due to a significant increase in metabolic capacity of the liver and cumulative
dose on the 40th and 120th minutes after ursodeoxycholic acid administration (p<0.01).
Conclusions. The use of ursodeoxycholic acid in addition to atorvastatin in patients with ischemic heart disease, co-existent
non-alcoholic fatty liver disease and obesity makes it possible to avoid the adverse effect of hypolipidemic therapy on the
functional status of the liver.
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Problem statement and analysis of the
recent research
Recently, an increasingly large number of studies have re-
vealed a relationship between non-alcoholic fatty liver dis-
ease (NAFLD) and cardiovascular disorders, atherosclerosis,
and dyslipoproteinemia [6]. NAFLD is considered as an in-
dependent predictor of cardiovascular diseases which plays
an important role in the development of ischemic heart dis-
ease (IHD) [1, 5]. The cross-over studies show that the num-
ber of cardiovascular complications in patients with NAFLD
increases due to the increase in the degree of histological
changes in the liver tissues [8]. In patients with IHD, NAFLD
significantly aggravates ischemic symptoms, increases the
occurrence of ventricular arrhythmia, worsens the parameters
of vegetative regulation of cardiac function and slows down
their improvement [3].
The drug most frequently used for treatment of this co-
morbidity is atorvastatin, which increases the patient’s life
expectancy and plays an important role in the primary and sec-
ondary prevention of cardiovascular diseases [9, 10]. Statins
have been proven to reduce the risk of unstable angina, cardiac
infarction and sudden coronary death by 30-40% (4S, CARE,
LIPID, WOSCOPS, ASCOT-LLA) in case of long-term thera-
pies [13]. According to several studies (REVERSAL, 2004;
ASTEROID, 2006; SATURN, 2011), statin therapy results in
a pronounced decrease in the levels of cholesterol and low-
density lipoproteins (LDL), rapid regression of atherosclerotic
plaques, cardiac remodeling and remodeling of blood vessels
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[12]. At the same time, in case of administering statins to
some patients, the phenomenon known as transaminitis is ob-
served; it is caused by the release of increased levels of liver
enzymes into the blood flow which may lead to side effect of
atorvastatin on the functional status of the liver, especially in
case of steatohepatitis [11].
Therefore, to eliminate side effects of statins, ursodeoxy-
cholic acid (UDCA) is prescribed to patients with NAFLD,
co-existent IHD and obesity [3].
UDCA therapy has been proven to be efficacious for
NAFLD and obesity due to its cytoprotective, immunomod-
ulatory and antiapoptotic action. UDCA prevents damage to
the cholangiocyte membranes by hydrophobic bile acids. It
contributes to the increase in the antioxidant defence through
the suppression of the activity of catalase, glutathione peroxi-
dase, glutathione-s-transferase as well as in the synthesis of
glutathione as well. UDCA prevents hepatocyte apoptosis in-
duced by the influence of hydrophobic bile acids, ethanol, etc.
Moreover, the drug has anti-inflammatory properties, namely
the ability to suppress the secretion of anti-inflammatory cy-
tokines and production of immunoglobulins [7].
The use of UDCA as a hepatoprotective agent during
comprehensive basic treatment of IHD improves the state
of the cardiovascular system. Hypertrophy regression, left
ventricular remodeling, an increased systolic motion of the
mitral ring, reduced incidence of ischemic manifestations
and ventricular arrhythmia are observed. It is of particular
importance during statin therapy allowing us to carry out
a long-term hypolipidemic therapy without side effects [2].
UDCA in comprehensive therapy enhances the effectiveness
of treatment and improves the functional status of the liver,
affecting the main pathogenetic links of the disease [4].
The objective of the research was to study the effect
of combined hypolipidemic therapy with atorvastatin and
ursodeoxycholic acid on the indices of blood lipids, liver
transaminase levels, functional status of the liver and the
course of NAFLD in patients with IHD and obesity.
1. Materials and methods
20 patients with NAFLD, co-existent IHD and obesity were
examined. They received ursodeoxycholic acid in addition to
atorvastatin for four weeks.
There were 12 (60%) males and 8 (40%) females. The
average age of patients was 55.6 ± 2.6 years; the average
disease duration was 4.8 ± 0.8 years.
All the patients underwent clinical, laboratory and instru-
mental examinations (anthropometry, blood lipid test, liver
transaminase test, electrocardiography, echocardiography, vis-
ceral ultrasonography and 13C-methacetin breath test).
Anthropometry involved the measurement of the height
and weight of the patient, calculating the body mass index
(BMI) by the Quetelet formula: BMI = (weight (kg)/(height
(m)2 )).
The inclusion criteria were verified IHD (stable angina,
post-infarction cardiosclerosis), the level of total cholesterol
exceeding 5 mmol/l, the level of LDL cholesterol exceeding 3
mmol/l and the level of serum triglycerides not exceeding 3.5
mmol/l.
The diagnosis of IHD was made based on the results of
coronarography, past myocardial infarction or positive tread-
mill test.
According to the guidelines of the International Diabetes
Federation (2005), to diagnose abdominal obesity, the waist
circumference (WC) was measured at the level of the umbili-
cus and assessed using the criteria for men WC>94 cm and
women WC>80 cm.
Blood lipids were estimated based on the serum levels of
total cholesterol (TC), triglycerides (TG), low-density lipopro-
tein cholesterol (LDL-C) and high-density lipoprotein choles-
terol (HDL-C). The activity of serum alanine transaminase
(ALT) and aspartate aminotransferase (AST) was determined
using the Reitman-Frankel transaminase method by means of
PLIVA-Lachema kit (the Czech Republic).
Ultrasonography of the hepatobiliary system was per-
formed on an empty stomach using Philips HDI 1500 ul-
trasound machine with a 3.5 mHz scanning sensor. The fol-
lowing parameters were determined: the size of hepatic lobes,
hepatic parenchyma density, the degree of fatty infiltration
of the liver, the presence of fibrosis and the diameter of the
vena portae (VP). Fatty infiltration of the liver was diagnosed
in case of enlarged liver, diffuse homogeneous increase in its
echogenicity, distal shadowing and dilated vena portae.
The functional status of the microsomal enzyme systems
of hepatocytes was assessed by means of 13C-methacetin
breath test (13CMBT) administering 75 g of methacetin la-
belled with non-radioactive isotope of carbon 13C orally.
The efficacy of prescribed treatment was evaluated after
the 4-week therapy using atorvastatin at a dose of 20 mg a day
and UDCA at a dose of 10 mg per kilogram of body weight
three times a day.
The obtained results were processed in Microsoft Excel
using the Student’s t-test and the Pearson correlation analysis.
2. Results and Discussion
In all the patients, abdominal visceral adipose tissue deposi-
tion was observed. The mean value of the BMI was 32.78 ±
0.91kg/m2.
According to anamnestic data, during outpatient examina-
tion, 17 (85.0%) patients complained of a feeling of heaviness
in the left hypochondrium, 16 (80%) patients reported gen-
eral weakness, 15 (75.0%) patients suffered from fatigue,
18 (90.0%) patients had bloating, 12 (60.0%) patients com-
plained of nausea and 16 (80.0%) patients reported bitter taste
in the mouth. The examination revealed that in 18 (90%)
cases, the lower edge of the liver extended beyond the costal
arch. Visceral ultrasonography revealed different stages of
hepatomegaly in 18 (90%) cases and hyperechogenicity of
hepatic parenchyma in 85.0% of cases. An important feature
was the detection of bend neck of the gallbladder with biliary
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retention in 60% of patients. Thus, according to the anam-
nesis, physical examination and visceral ultrasonography, in
patients of this group the symptoms of fatty infiltration of the
liver were observed.
The four-week combination therapy with atorvastatin and
UDCA for patients with IHD and co-existent NAFLD resulted
in a significant reduction of the level of the pro-atherogenic
fractions of blood lipids (p<0.01) (Table 1).
In 30% of patients increased AST level was observed and
20% had increased ALT level. At the same time, there were
no significant differences between the levels of liver transam-
inases, although there was a tendency towards reduction in
the mean concentration of ALT from 0.61 ± 0.06 to 0.53 ±
0.03 umol/l and AST from 0.50 ± 0.04 to 0.46 ± 0.02 umol/l
(p>0.05).
When assessing the functional status of the microsomal
enzyme systems of hepatocytes using 13C-methacetin breath
test in patients with comorbidity, a significant increase in
metabolic capacity of the liver and cumulative dose on the
40th and 120th minutes after administering UDCA was found
(p<0.01) (Table 2). The results of the study showed that the
use of combination therapy with atorvastatin and UDCA in
patients with the given comorbidity contributed to the im-
provement of general condition of patients. On the one hand,
UDCA reduced biliary retention; on the other hand, ator-
vastatin decreased the concentration of the pro-atherogenic
fractions of blood lipids. Combination therapy with atorvas-
tatin and UDCA was more effective in reducing the levels of
triglycerides compared to the use of atorvastatin only [13].
However, significant positive changes in the indicators
of 13C-methacetin breath test which were manifested as the
increase in hepatic metabolism and cumulative doses on the
40th and 120th minutes were the most important.
Thus, the use of UDCA with atorvastatin in patients with
IHD, co-existent NAFLD, and obesity makes it possible to
reduce the adverse effects of hypolipidemic therapy in case of
disturbed functional status of the liver.
3. Conclusions
1. The use of UDCA in combination with atorvastatin
results in a significant reduction in the concentration of
the pro-atherogenic fractions of blood lipids in patients
with NAFLD, co-existent IHD and obesity.
2. Combination therapy with atorvastatin and UDCA in-
patients with comorbid pathology results in significant
improvement of functional status of the liver due to the
increase in metabolic capacity of the liver and metabolic
rate on the 40th and 120th minutes.
4. Prospects for further research
Prospects for further research consist in developing the crite-
ria for selecting patients with IHD, co-existent NAFLD and
obesity for protracted treatment with statins.
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AST, umol/l 0.50 ± 0.04 0.46 ± 0.02 >0.05
Note.
n – the number of patients in the group.
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